Screening for Islet Autoantibodies in Families of Type 1 Diabetes Patients
The Israeli Study for Islet Autoantibodies Screening in Families of Type-1 Diabetes Patients
This study is testing a new way to check if family members of people with Type 1 Diabetes have certain antibodies to see if they might be at risk for diabetes and to offer them support and education if needed.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 2 Years to 45 Years |
| Sex | All |
| Sponsor | Rabin Medical Center Academic / other |
| Locations | 1 site (Petach-Tikva) |
| Trial ID | NCT05788341 on ClinicalTrials.gov |
What this trial studies
This research program aims to screen relatives of individuals with Type 1 Diabetes (T1D) for the presence of Islet Autoantibodies (IA) using a highly sensitive detection method. Participants, including children and adults aged 2-45, will be recruited from clinics across Israel. If IA is detected, individuals will undergo further testing and be invited to an educational program focused on diabetes management and prevention strategies. The program will also address stress management for families affected by T1D.
Who should consider this trial
Good fit: Ideal candidates are first-degree relatives of known T1D patients aged 2-45 years who can provide informed consent.
Not a fit: Patients with any known type of diabetes or those currently using systemic immunosuppressive agents may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could lead to early detection of T1D in at-risk individuals, allowing for timely intervention and education.
How similar studies have performed: Other studies have shown success in early detection and intervention strategies for Type 1 Diabetes, making this approach promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * First degree family member (sibling or parent) of a known T1D patient * Age 2-45 years * Signing an informed consent Exclusion Criteria: * Known diabetes of any kind (type 2, MODY) * Have a previous history of being treated with insulin or oral diabetes medications. * Currently be using systemic immunosuppressive agents (topical and inhaled agents are acceptable)
Where this trial is running
Petach-Tikva
- Schneider Children Medical Center of Israel — Petach-Tikva, Israel (Recruiting)
Study contacts
- Study coordinator: Alona Hamou, Msc
- Email: alonah@clalit.org.il
- Phone: 972-545-950277
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.